Simulations Plus (SLP) Buys Pro-ficiency Holdings for $100M

Core Insights - Simulations Plus has acquired Pro-ficiency Holdings, Inc. for approximately $100 million, enhancing its presence in drug development from pre-clinical to commercialization [1][9] - The acquisition expands Simulations Plus' total addressable market by adding $4 billion in revenue opportunities in clinical simulations training, analytics, and medical communications [11] Financial Performance - Software revenues, which account for 63% of total quarterly revenues, increased by 11% year over year to $11.6 million, while service revenues (37%) improved by 27% to $6.7 million [4] - Overall sales for the last reported quarter rose by 16%, driven by higher software revenues in Clinical Pharmacology & Pharmacometrics and Cheminformatics business units [12] Product Development - The company launched the GastroPlus X (GPX) platform in May 2024, which integrates various modeling and simulation tasks, significantly reducing time spent on model setup and data management [5] - The DILIsym software licenses were renewed by the FDA for the seventh consecutive time, aiding pharmaceutical development teams in understanding compounds and safe dosing methods [14] Market Position - Simulations Plus is recognized in the biosimulation market, focusing on drug discovery, development, research, and regulatory submissions [3] - The acquisition of Pro-ficiency is expected to strengthen client relationships and create cross-selling opportunities within the life sciences sector [11]